Fig. 2

Percentage change from baseline in quantitative imaging measures at mid- and post-treatment. At mid-treatment, no significant differences were observed in change in tumor longest dimension between pathologic responders and non-responders (A), while greater decreases in peak PE (p = 0.03, B) and SUVmax (p = 0.05, C) were observed in patients who achieved RCB 0/I versus II/III at surgery. At post-treatment, patients who achieved RCB 0/I exhibited a significantly greater decrease in all three imaging metrics (D–F) compared to patients with RCB II/III disease. *p < 0.05; **p < 0.01